AKAN AKANDA CORP.

NEUTRAL Impact: 4/10 6-K
Horizon days Filed Apr 7, 2026 Processed 2mo ago SEC 0001213900-26-041103
Notable filing: 6-K
Latest settled — T+20d
AKAN ▲ +865.22% at T+20d
NEUTRAL call ✓ call won +865.22% · α vs SPY +856.67% · entry $3.11 → $30.00
Next anchor: T+60d in 22d
Last close $14.65 (close Jun 8) · +371.35% from $3.11 entry
Entry anchored
Apr 7, 10:49 AM ET
via Databento tick
T+1d
-3.91%
call -3.91% · α -4.49%
$2.99
settled 2mo ago
T+5d
+6.50%
call +6.50% · α +2.98%
$3.31
settled 8w ago
T+20d
+865.22%
call +865.22% · α +856.67%
$30.00
settled 5w ago
T+60d
call — · α —
in 22d

Price Chart

Loading chart...

Executive Summary

Akanda Corp. adjourned its special shareholder meeting on March 31, 2026, due to lack of quorum, and rescheduled it for April 27, 2026. The company will use the additional time to solicit shareholder proxies to meet the 10% voting threshold required for a quorum.

Actionable Insight

Traders should monitor for follow-up filings regarding proxy solicitation progress and whether quorum is achieved at the April 27 meeting, which could impact governance decisions. Low market cap ($2M) increases sensitivity to potential changes in control or strategy.

Key Facts

  • Special shareholder meeting convened on March 31, 2026, was adjourned due to absence of quorum.
  • Quorum requires at least two shareholders representing not less than 10% of outstanding voting shares.
  • Meeting rescheduled for April 27, 2026, at the same location and time.
  • Record date for voting remains February 26, 2026; previously submitted proxies remain valid unless revoked.
  • Company is actively soliciting shareholder participation to ensure quorum at the reconvened meeting.

Financial Impact

No immediate financial impact disclosed; adjournment delays potential shareholder decisions but does not alter financial position.

quorumshareholder participationgovernance

Risk Factors

  • Failure to achieve quorum at the reconvened meeting could delay or prevent critical corporate actions.
  • Low shareholder engagement may signal broader governance or investor confidence issues.

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-041103
Document: ea028535501ex99-1.htm0001213900-26-041103
Document: 0001213900-26-041103-index-headers.html0001213900-26-041103
Document: 0001213900-26-041103-index.html0001213900-26-041103
Document: 0001213900-26-041103.txt0001213900-26-041103
7 reports for AKAN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AKAN — sortable, filterable
Type Now
Jun 9, 2026
today
20-F
BEARISH ★ 8/10
$13.49 awaiting T+5awaiting T+5$14.65 (−8.60%)
May 22, 2026
18d ago
6-K
BEARISH ★ 7/10
$23.86 $16.97▲ +28.88%▲ +29.96%$14.65 (+38.60%)
May 13, 2026
27d ago
6-K
NEUTRAL ★ 4/10
$24.90 $23.46▼ −5.78%▼ −5.07%$14.65 (−41.16%)
Apr 29, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$25.99 $30.00▲ +15.43%▲ +12.32%$14.65 (−43.63%)
Apr 9, 2026
8w ago
6-K
NEUTRAL ★ 4/10
$2.99 $3.29▲ +10.16%▲ +6.98%$14.65 (+390.54%)
Apr 7, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$3.11 $3.31▲ +6.50%▲ +2.98%$14.65 (+371.35%)
Mar 20, 2026
11w ago
F-1/A
BEARISH ★ 5/10
$3.76 $2.71▲ +28.02%▲ +24.46%$14.65 (−289.49%)
Showing 7 of 7

US Market Status

Market Closed — Opens in 3h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access